serin
proteas
capabl
cleav
influenza
viru
ha
wherea
serin
proteas
inhibitor
serpin
inhibit
ha
cleavag
variou
cell
type
kallikreinrel
peptidas
also
known
tissu
kallikrein
wide
distribut
serin
proteas
kallistatin
serpin
synthes
mainli
liver
rapidli
secret
circul
form
complex
inhibit
activ
investig
role
kallistatin
influenza
viru
infect
show
level
increas
wherea
kallistatin
decreas
lung
mice
influenza
viru
infect
cleav
ha
molecul
consequ
enhanc
viral
product
contrast
kallistatin
inhibit
take
data
togeth
determin
kallistatin
contribut
pathogenesi
influenza
viru
affect
cleavag
ha
peptid
inflammatori
respons
studi
provid
proof
principl
potenti
therapeut
applic
kallistatin
inhibitor
influenza
sinc
proteolyt
activ
also
enhanc
infect
virus
kallistatin
kallikrein
inhibitor
may
explor
antivir
agent
virus
nfluenza
import
acut
respiratori
diseas
human
anim
influenza
epidem
pandem
constant
threat
human
health
factor
implic
high
morbid
mortal
influenza
viru
infect
includ
robust
cytokin
product
cytokin
storm
excess
inflammatori
infiltr
virusinduc
lung
tissu
destruct
although
pulmonari
inflammatori
respons
may
facilit
viru
clearanc
often
caus
sever
lung
injuri
interact
influenza
viru
host
factor
crucial
viru
replic
therefor
understand
interplay
viral
host
factor
may
provid
new
target
antivir
therapi
hemagglutinin
ha
present
envelop
influenza
viru
import
determin
viral
virul
pathogenesi
infect
influenza
viru
initi
cleavag
subunit
lead
exposur
hydrophob
n
terminu
fusion
peptid
facilit
fusion
viral
envelop
host
endosom
membran
proteolyt
cleavag
precursor
ha
molecul
host
trypsinlik
proteas
requir
viral
infect
ha
cleavag
site
extern
loop
link
loop
shown
cleav
host
serin
proteas
cell
cultur
thrombin
plasmin
bloodclot
factor
xa
acrosin
miniplasmin
proteas
human
respiratori
lavag
transmembran
proteas
serin
member
human
airway
trypsinlik
proteas
hat
howev
specif
proteas
respons
ha
cleavag
human
respiratori
tract
still
unclear
contrast
serin
proteas
inhibitor
serpin
shown
inhibit
cleavag
ha
thu
suppress
influenza
viru
activ
includ
aprotinin
leupeptin
pulmonari
surfact
inhibitor
plasminogen
activ
human
mucu
proteas
inhibitor
aprotinin
therapeut
effect
influenza
human
mice
suppress
ha
cleavag
inflamm
human
kallikrein
serin
proteas
compris
kallikreinrel
peptidas
klk
plasma
kallikrein
also
known
klk
compos
member
involv
proteolyt
cascad
implic
pathophysiolog
process
also
known
tissu
kallikrein
respons
cleavag
kininogen
releas
kinin
bradykininrel
peptid
mediat
regul
smooth
muscl
contract
vascular
permeabl
vascular
cell
growth
inflammatori
cascad
electrolyt
balanc
neutrophil
chemotaxi
pain
induct
synthes
proenzym
prekallikrein
activ
plasmin
plasma
kallikrein
ubiquit
express
system
exert
variou
biolog
activ
cardiovascular
renal
central
nervou
immun
system
addit
express
activ
resid
epitheli
cell
alveolar
macrophag
recruit
inflammatori
cell
neutrophil
kallistatin
first
identifi
human
plasma
bind
protein
specif
inhibitor
detect
variou
tissu
cell
bodi
fluid
kallistatin
uniqu
phenylalanin
residu
confer
excel
inhibitori
specif
toward
inhibit
activ
kallistatin
also
exhibit
pleiotrop
effect
independ
system
reduct
blood
pressur
vasodilat
inhibit
inflamm
angiogenesi
tumor
growth
howev
role
kallikreinkinin
system
kallistatin
viral
infect
remain
larg
unknown
among
differ
klk
physiolog
function
rel
well
establish
ubiquit
express
express
prostat
physiolog
role
klk
remain
larg
unknown
primari
kiningener
enzym
lung
kinin
level
elev
respiratori
tract
patient
asthma
rhiniti
bronchiti
pneumonia
moreov
experiment
rhinoviru
infect
individu
asthma
increas
activ
accompani
increas
interleukin
express
inflammatori
respons
widespread
distribut
enhanc
potenti
involv
kinin
gener
multipl
site
moder
express
lung
trachea
also
exist
ductal
gland
includ
nasal
gland
salivari
gland
small
gland
aerodigest
tract
addit
express
activ
resid
epitheli
cell
alveolar
macrophag
recruit
inflammatori
cell
neutrophil
sinc
involv
mani
airway
diseas
includ
asthma
nasal
allergi
chronic
bronchiti
chose
studi
impact
influenza
viru
infect
kallistatin
natur
occur
inhibitor
ubiquit
express
includ
human
respiratori
system
may
also
play
role
influenza
viru
infect
either
depend
independ
aim
studi
investig
potenti
role
kallistatin
influenza
viru
infect
test
whether
cleav
activ
ha
promot
viral
infect
whether
kallistatin
inhibit
viral
product
amelior
influenza
viru
pathogenesi
result
indic
upregul
influenza
viru
infect
could
cleav
ha
molecul
enhanc
viral
replic
cultur
cell
effect
could
abrog
kallistatin
treatment
furthermor
lentivirusmedi
kallistatin
gene
deliveri
confer
protect
influenza
inhibit
ha
cleavag
allevi
lung
inflamm
collect
find
provid
insight
interplay
influenza
viru
host
kallikreinkallistatin
system
result
also
impli
potenti
therapeut
use
kallistatin
inhibitor
influenza
cell
virus
protein
mice
mdck
cell
obtain
american
type
cultur
collect
mdck
cell
cultur
dulbecco
modifi
eagl
minim
essenti
medium
dmem
supplement
fetal
bovin
serum
hyclon
logan
ut
usa
mm
lglutamin
gentamicin
gml
co
human
bronchial
epitheli
cell
line
obtain
p
l
kuo
origin
american
type
cultur
collect
cultur
keratinocyt
serumfre
medium
invitrogen
carlsbad
ca
usa
contain
ngml
human
recombin
epiderm
growth
factor
ngml
bovin
pituitari
extract
supplement
ngml
insulin
ngml
hydrocortison
influenza
virus
propag
titrat
describ
previous
produc
stock
influenza
virus
contain
uncleav
mdck
cell
infect
influenza
viru
multipl
infect
moi
serumfre
dmem
contain
trypsin
gml
capabl
cleavag
activ
ha
h
wash
three
time
phosphatebuff
salin
pb
cultur
replenish
serumfre
dmem
absenc
trypsin
h
supernat
cell
cultur
clear
centrifug
aliquot
store
viru
stock
use
ha
cleav
plasmin
convert
plasminogen
plasminogen
activ
present
calf
serum
rule
possibl
serum
plasminogen
cultur
medium
wash
mdck
cell
extens
pb
cultur
cell
serumfre
medium
absenc
trypsin
vitro
experi
lentivir
vector
psinnul
deriv
addgen
plasmid
addgen
cambridg
usa
code
region
remov
digest
spei
bamhi
result
larg
fragment
plasmid
fill
dna
polymeras
subsequ
selflig
dna
ligas
recombin
lentivirus
lvk
lvgfp
lvnull
encod
human
kallistatin
green
fluoresc
protein
gfp
carri
transgen
produc
transient
transfect
cell
pwpxlkallistatin
pwpxl
psinnul
respect
along
packag
construct
vesicular
stomat
viru
g
protein
vsvg
express
plasmid
work
influenza
virus
recombin
lentivir
vector
carri
biosafeti
level
laboratori
recombin
rat
protein
produc
purifi
previous
describ
recombin
human
kallistatin
protein
purchas
abcam
cambridg
unit
kingdom
femal
mice
obtain
laboratori
anim
center
nation
cheng
kung
univers
experiment
protocol
adher
rule
anim
protect
act
taiwan
approv
anim
care
use
committe
nation
cheng
kung
univers
iacuc
number
analysi
ha
cleavag
recombin
ha
protein
ng
l
salin
deriv
influenza
virus
purchas
sino
biolog
inc
beij
china
incub
concentr
rang
gml
h
detect
cleavag
influenza
viru
per
se
influenza
virus
pfu
l
serumfre
dmem
incub
concentr
gml
h
incub
pattern
ha
cleavag
analyz
immunoblot
analysi
antibodi
differ
subtyp
ha
investig
whether
kallistatin
could
inhibit
ha
cleavag
recombin
ha
protein
ng
l
salin
deriv
influenza
virus
incub
kallistatin
gml
andor
gml
influenza
viru
particl
pfu
l
serumfre
dmem
incub
kallistatin
gml
andor
gml
h
incub
pattern
ha
cleavag
analyz
immunoblot
analysi
antibodi
differ
subtyp
ha
immunoblot
analysi
immunoblot
analysi
perform
detect
kallistatin
influenza
viru
ha
use
standard
method
primari
antibodi
use
immunoblot
includ
mous
monoclon
antiprekallikreinkallikrein
antibodi
abcam
mous
antihuman
kallistatin
monoclon
antibodi
ascit
fluid
goat
antiinfluenza
viru
antiserum
virostat
portland
usa
mous
antiinfluenza
viru
ha
monoclon
antibodi
santa
cruz
biotechnolog
dalla
tx
usa
rabbit
antiinfluenza
viru
ha
antibodi
sino
biolog
inc
rabbit
antiinfluenza
viru
ha
antibodi
sino
biolog
inc
mous
monoclon
peroxidas
antibodi
sigmaaldrich
st
loui
mo
usa
horseradish
peroxidaseconjug
donkey
antigoat
goat
antimous
goat
antirabbit
igg
jackson
west
grove
pa
usa
use
secondari
antibodi
appropri
proteinantibodi
complex
detect
ecl
system
millipor
bedford
usa
visual
biospectrum
imag
system
uvp
inc
upland
ca
usa
kodak
xar
film
eastman
kodak
co
rochest
ny
usa
rel
intens
protein
band
quantifi
use
publicdomain
imag
analysi
softwar
packag
imagej
us
nation
institut
health
uvp
biospectrum
imag
system
rtpcr
analysi
total
rna
isol
trizol
reagent
invitrogen
reverseit
firststrand
synthesi
kit
appli
biosystem
foster
citi
ca
usa
use
cdna
synthesi
follow
primer
use
revers
transcript
rt
pcr
analysi
mous
forward
revers
mous
kallistatin
forward
revers
mous
dehydrogenas
gapdh
forward
revers
pcr
condit
gapdh
cycl
pcr
condit
kallistatin
cycl
gapdh
gene
use
intern
control
gene
normal
express
gene
interest
rel
intens
band
quantifi
use
uvp
biospectrum
imag
system
cytotox
plaqu
assay
confluent
mdck
cell
cultur
plate
triplic
infect
influenza
viru
presenc
absenc
kallistatin
h
moreov
mdck
cell
grown
dish
infect
lvk
lvnull
moi
left
uninfect
h
dmem
contain
cosmic
calf
serum
hyclon
logan
ut
usa
cell
seed
cellswel
plate
cultur
ml
dmem
contain
cosmic
calf
serum
h
cultur
replenish
serumfre
dmem
addit
h
subsequ
cell
infect
influenza
viru
moi
mock
infect
presenc
absenc
gml
serumfre
dmem
cultur
h
viabl
cell
stain
crystal
violet
well
scan
crystal
violet
stain
quantifi
use
imagej
softwar
titer
influenza
viru
quantifi
plaqu
assay
briefli
confluent
mdck
cell
well
grown
plate
incub
ml
serial
dilut
viru
sampl
serumfre
dmem
co
h
cell
wash
pb
replenish
ml
dmem
contain
cosmic
calf
serum
trypsin
gml
agaros
lonza
rockland
usa
h
cell
fix
crystal
violet
contain
formalin
h
plaqu
count
altern
viral
titer
determin
tissu
cultur
infect
dose
tcid
method
determin
level
kallistatin
mice
follow
influenza
viru
infect
mice
intranas
inocul
pfu
influenza
viru
salin
lung
tissu
examin
kallistatin
express
immunoblot
rtpcr
analys
day
postinfect
pi
kallistatin
gene
deliveri
mice
intranas
inocul
transduct
unit
tu
lvk
lvgfp
salin
three
consecut
day
one
day
treatment
lentivir
vector
mice
intranas
inocul
pfu
influenza
viru
mice
monitor
daili
ill
death
day
viral
infect
similar
experi
mice
treat
lvk
lvgfp
challeng
influenza
viru
pfu
sacrif
day
pi
histolog
analysi
histolog
analysi
mous
lung
prepar
fix
buffer
formalin
h
dehydr
grade
alcohol
embed
paraffin
section
section
mount
onto
glass
slide
stain
hematoxylin
eosin
h
e
dako
carpinteria
ca
usa
inflammatori
chang
basi
number
inflammatori
cell
tissu
damag
lung
examin
histolog
h
estain
longitudin
cross
section
grade
chang
score
mild
score
moder
score
sever
score
previous
describ
section
review
score
blind
fashion
pathologist
ccl
elisa
nitric
oxid
detect
confluent
cell
cellswel
grown
plate
infect
pfu
influenza
viru
equival
moi
respect
h
condit
medium
assess
kallistatin
content
enzymelink
immunosorb
assay
elisa
describ
previous
detect
rang
human
kallistatin
elisa
ngml
bronchoalveolar
lavag
bal
perform
two
intratrach
inject
ml
salin
alveolar
space
influenza
virusinfect
mice
day
pi
bal
fluid
total
ml
collect
gentl
suction
centrifug
cellfre
supernat
collect
store
subsequ
analysi
level
mous
tumor
necrosi
factor
alpha
gamma
interferon
monocyt
chemotact
protein
macrophag
inflammatori
protein
bal
fluid
serum
detect
elisa
kit
r
system
minneapoli
mn
usa
serum
level
estim
measur
accumul
use
griess
reagent
statist
analysi
data
express
mean
standard
deviat
sd
differ
effici
ha
cleavag
compar
twoway
analysi
varianc
anova
repeat
measur
surviv
analysi
perform
use
kaplanmei
surviv
curv
logrank
test
remain
data
analyz
oneway
anova
bonferroni
post
hoc
test
student
test
differ
consid
signific
p
valu
statist
test
perform
use
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
investig
whether
chang
kallistatin
level
occur
acut
influenza
viru
infect
determin
protein
mrna
level
kallistatin
lung
mice
intranas
infect
influenza
viru
immunoblot
analysi
show
upregul
wherea
express
level
kallistatin
remain
similar
lung
mice
day
pi
fig
b
rtpcr
analysi
reveal
express
mrna
progress
increas
time
wherea
kallistatin
mrna
level
markedli
decreas
day
pi
lung
mice
infect
influenza
viru
fig
figur
show
human
bronchial
epitheli
cell
infect
influenza
viru
moi
significantli
secret
smaller
amount
kallistatin
mockinfect
cell
howev
content
detect
limit
assay
ngml
supernat
either
mockinfect
infect
cell
elisa
condit
data
shown
collect
result
indic
mrna
protein
level
increas
wherea
kallistatin
mrna
level
decreas
lung
influenza
virusinfect
mice
cleav
ha
domin
human
subtyp
influenza
viru
context
ha
protein
viru
particl
given
serin
proteas
upregul
lung
mice
influenza
viru
infect
investig
whether
capabl
cleav
ha
molecul
context
purifi
protein
figur
show
dosedepend
cleav
recombin
ha
protein
influenza
virus
subunit
furthermor
cleavag
effici
appear
differ
among
variou
strain
influenza
viru
compar
cleavag
effici
use
gml
cleav
recombin
ha
protein
deriv
differ
subtyp
h
analyz
cleavag
profil
immunoblot
respect
antiha
antibodi
shown
fig
effici
cleav
ha
molecul
three
viral
strain
test
howev
ha
molecul
influenza
viru
cleav
low
level
determin
percentag
ha
cleavag
densitometr
analysi
immunoblot
shown
fig
quantit
analysi
reveal
cleav
ha
protein
influenza
virus
effici
ha
protein
influenza
viru
fig
examin
whether
cleav
ha
surfac
viru
particl
figur
show
treatment
increas
proteolyt
cleavag
viral
ha
surfac
influenza
viru
dosedepend
manner
howev
cleavag
viral
ha
surfac
influenza
viru
less
effici
compar
cleavag
purifi
ha
pro
tein
higher
concentr
requir
cleav
ha
context
whole
viru
particl
taken
togeth
result
indic
cleav
ha
domin
human
subtyp
influenza
viru
treatment
enhanc
influenza
viru
product
vitro
studi
whether
cleavag
viral
ha
correl
extent
cytopath
effect
cpe
infect
cell
mdck
cell
infect
either
influenza
viru
treat
variou
concentr
follow
examin
cpe
crystal
violet
stain
day
pi
cultur
well
scan
crystal
violet
stain
quantifi
imag
analysi
softwar
shown
fig
treatment
enhanc
virusinduc
cpe
left
result
reduct
viabl
cell
stain
crystal
violet
right
cell
infect
influenza
viru
accordingli
cell
treat
strain
viru
presenc
produc
higher
viral
yield
without
treatment
fig
case
influenza
viru
weak
enhanc
virusinduc
cpe
seen
much
higher
dose
fig
result
higher
viral
product
infect
cell
fig
data
consist
fig
show
effici
cleav
ha
molecul
influenza
viru
ha
molecul
influenza
viru
taken
togeth
result
indic
cell
infect
influenza
viru
suscept
ha
cleavag
presenc
produc
higher
yield
influenza
viru
without
treatment
facilit
visual
ha
band
blot
film
multipl
exposur
analyz
ensur
signal
could
detect
exposur
time
longer
band
band
increas
sensit
band
quantifi
densitometr
analysi
ratio
plu
divid
plu
plu
repres
ha
cleavag
effici
shown
bottom
blot
result
repres
three
independ
experi
b
cleavag
ha
molecul
gml
h
note
lane
shown
influenza
viru
ha
protein
cut
individu
blot
facilit
comparison
cleavag
effici
differ
ha
subtyp
individu
exposur
time
among
ha
protein
deriv
differ
influenza
viru
strain
ident
sinc
subtyp
cleav
quickli
easili
subtyp
subtyp
partial
degrad
result
weaker
stain
howev
seemingli
unusu
result
occur
gml
less
use
result
repres
three
independ
experi
c
effici
ha
cleavag
percentag
ha
cleavag
determin
densitometri
immunoblot
analysi
shown
panel
b
valu
shown
mean
sd
three
independ
experi
cleavag
influenza
viru
influenza
virus
pfu
l
serumfre
medium
incub
variou
concentr
gml
trypsin
serv
posit
control
h
subtyp
stain
weakli
gml
use
result
partial
degrad
band
quantifi
describ
panel
result
repres
three
independ
experi
enhanc
influenza
viru
product
cleavag
activ
ha
next
determin
whether
kallistatin
natur
occur
inhibitor
inhibit
ha
cleavag
therebi
reduc
viral
product
treatment
recombin
kallistatin
protein
dosedepend
inhibit
cleavag
recombin
ha
protein
influenza
acalifornia
virus
fig
importantli
kallistatin
also
inhibit
ha
cleavag
induc
surfac
viru
particl
fig
shown
fig
mdck
cell
treat
kallistatin
protect
influenza
virusinduc
cpe
notabl
treatment
also
abrog
effect
potenti
virusinduc
cpe
accordingli
cell
infect
influenza
viru
presenc
kallistatin
reduc
viral
yield
compar
untreat
cell
fig
furthermor
treatment
kallistatin
also
significantli
allevi
elev
viral
titer
fig
collect
result
demonstr
exogen
treatment
kallistatin
protein
inhibit
ha
cleavag
reduc
viru
product
cell
transduc
kallistatin
gene
resist
influenza
viru
infect
addit
use
exogen
ad
kallistatin
also
use
endogen
overexpress
kallistatin
demonstr
antiinfluenza
viru
activ
shown
fig
cell
viabil
significantli
higher
mdck
cell
transduc
lvk
transduc
control
vector
lvnull
follow
influenza
viru
infect
either
presenc
absenc
secret
kallistatin
condit
medium
mdck
cell
transduc
lvk
verifi
elisa
fig
estim
ng
kallistatin
secret
mdck
cell
transduc
kallistatin
gene
furthermor
lvkstransduc
cell
produc
significantli
less
viru
lvnulltransduc
cell
follow
influenza
viru
infect
presenc
fig
taken
togeth
result
demonstr
endogen
overexpress
kallistatin
reduc
virusinduc
cpe
viru
product
treatment
lvk
protect
mice
lethal
influenza
viru
challeng
allevi
lung
inflamm
intranas
inocul
lentivir
vector
report
target
airway
epitheli
cell
type
ii
alveolar
cell
lung
endothelium
mice
test
whether
antiinfluenza
viru
activ
kallistatin
seen
vitro
also
manifest
vivo
treat
mice
intranas
lvk
lvgfp
consecut
day
next
day
mice
challeng
lethal
dose
influenza
viru
express
human
kallistatin
lung
mice
receiv
lvk
confirm
fig
treatment
lvk
significantli
protect
mice
lethal
influenza
viru
challeng
compar
treatment
lvgfp
salin
fig
viral
titer
also
significantli
reduc
bal
fluid
infect
mice
pretreat
lvk
compar
pretreat
lvgfp
fig
kallistatin
regul
secret
modul
releas
cytokin
includ
intercellular
adhes
molecul
examin
whether
lvk
gene
deliveri
reduc
level
proinflammatori
cytokin
chemokin
bal
fluid
mice
pretreat
lvk
produc
lower
level
bal
fluid
day
pi
pretreat
lvgfp
fig
nevertheless
statist
differ
level
bal
fluid
day
pi
found
lvksand
lvgfptreat
mice
data
shown
similarli
serum
level
lvksand
lvgfptreat
mice
h
pi
significantli
differ
data
shown
term
lung
patholog
kallistatin
gene
deliveri
reduc
lung
injuri
decreas
infiltr
inflammatori
cell
mice
infect
influenza
viru
fig
furthermor
lung
histolog
score
lower
lvkstreat
mice
lvgfpor
salinetr
control
mice
fig
collect
result
demonstr
lentivirusmedi
kallistatin
gene
deliveri
significantli
reduc
viral
product
respiratori
tract
amelior
lung
patholog
protect
mice
lethal
influenza
viru
infect
aberr
kallikreinkinin
signal
play
import
role
wide
rang
patholog
process
includ
inflamm
prekallikrein
inact
precursor
kallikrein
wide
distribut
activ
inflammatori
condit
mous
model
dual
infect
influenza
viru
serratia
marcescen
administr
proteas
serratia
enhanc
influenza
viru
replic
gener
larger
amount
plasmin
activ
lung
contribut
enhanc
proteolyt
cleavag
ha
ferret
model
influenza
lysyl
bradykinin
bradykinin
produc
ferret
nasal
secret
ratio
similar
seen
human
influenza
viru
infect
suggest
ferret
kallikrein
induc
function
respiratori
tract
ferret
influenza
limit
inform
far
host
proteas
involv
influenza
viru
activ
apart
upregul
mice
influenza
viru
infect
demonstr
present
studi
present
respiratori
tract
healthi
individu
report
cleav
activ
ha
although
shown
involv
skin
inflamm
atop
dermat
role
influenza
viru
infect
yet
elucid
lung
trachea
abund
wherea
moder
express
kallistatin
shown
display
high
specif
toward
klk
strong
inhibitor
weak
inhibitor
shown
inhibit
wherea
also
inhibit
proteinas
c
inhibitor
whether
two
natur
inhibitor
physiolog
relev
regul
healthi
diseas
state
infect
inflamm
await
clarif
addit
worthwhil
examin
whether
kallikrein
plasma
kallikrein
klk
member
also
upregul
influenza
viru
infect
role
cleavag
activ
ha
influenza
viru
undergo
antigen
variat
allow
viru
evad
host
immun
respons
may
result
viru
replic
select
resist
current
avail
antiinfluenza
drug
increas
emerg
drugresist
influenza
viru
strain
reinforc
need
identifi
new
therapeut
target
develop
effect
antivir
agent
influenza
viru
cellular
factor
signal
pathway
essenti
viral
replic
cycl
may
favor
target
viral
factor
vitro
anim
studi
demonstr
kallistatin
exert
antiinfluenza
viru
activ
presum
bind
thu
counteract
cleavag
activ
ha
endogen
human
rat
complex
demonstr
plasma
variou
bodi
fluid
amelior
lung
inflamm
virusinfect
mice
may
attribut
antiinfluenza
viru
antiinflammatori
activ
kallistatin
sinc
kallistatin
exert
pleiotrop
effect
either
depend
independ
presum
kallistatin
inhibit
cleavag
activ
ha
bind
may
also
attenu
inflamm
andindepend
manner
influenza
viru
infect
find
provid
impetu
develop
antiinfluenza
viru
agent
base
kallistatin
klk
inhibitor
target
kallikreinkinin
system
use
recombin
human
kallistatin
treat
influenza
virusinfect
mice
via
intratrach
rout
treatment
dose
schedul
optim
sampl
size
may
larg
enough
differ
bodi
weight
loss
surviv
time
significantli
differ
kallistatintr
control
mice
nevertheless
kallistatintr
mice
appear
exhibit
less
bodi
weight
loss
longer
surviv
time
see
fig
supplement
materi
result
suggest
local
administr
kallistatin
protein
might
effect
amelior
influenza
patholog
moreov
identif
novel
smallmolecul
inhibitor
highthroughput
screen
may
deserv
explor
develop
antiinfluenza
drug
proteolyt
cleavag
ha
determin
suscept
ha
molecul
influenza
viru
strain
substrat
specif
host
proteas
ha
cleavag
occur
c
terminu
singl
arginin
lysin
residu
locat
adjac
glycin
residu
present
studi
use
two
one
one
ha
recombin
protein
analyz
suscept
cleavag
found
ha
molecul
influenza
viru
wellstudi
neurotrop
strain
could
cleav
effici
among
four
viru
strain
amino
acid
substitut
near
ha
cleavag
site
affect
cleavabl
host
proteas
consensu
sequenc
cleavag
site
iqsrg
cleavag
occur
arginin
residu
posit
glycin
residu
posit
howev
influenza
viru
contain
tyrosin
iqyrg
posit
allow
effici
ha
cleavag
plasmin
independ
trypsin
thu
replac
conserv
serin
residu
tyrosin
residu
posit
influenza
viru
may
account
part
effici
cleavag
similar
plasmin
cleavag
activ
ha
effici
vari
wide
among
ha
subtyp
depend
proteas
impli
characterist
proteas
may
influenc
host
rang
adapt
influenza
viru
cleavag
specif
effici
variou
ha
subtyp
requir
investig
larg
sampl
size
clinic
set
lower
level
plasma
intestin
kallistatin
detect
patient
sever
communityacquir
pneumonia
inflammatori
bowel
diseas
respect
elev
circul
synovi
level
kallistatin
found
patient
rheumatoid
arthriti
murin
model
acut
influenza
viru
infect
express
increas
wherea
express
kallistatin
decreas
lung
suggest
kallistatin
may
play
role
influenza
viru
infect
verifi
import
endogen
kallistatin
host
defens
influenza
viru
infect
gene
knockout
mice
would
use
tool
address
question
host
inflammatori
respons
play
import
role
defens
influenza
respons
may
sometim
contribut
immunopatholog
studi
receptor
knockout
mice
reveal
mediat
acut
lung
inflammatori
patholog
enhanc
surviv
influenza
virusinfect
mice
present
studi
show
influenza
viru
infect
accompani
product
bal
fluid
influenza
viru
infect
induc
inflammasom
activ
produc
human
macrophag
caspas
pathway
viru
infect
activ
sever
transcript
factor
involv
induct
cytokin
chemokin
gene
express
influenza
viru
infect
activ
nfb
import
virusinduc
cytokin
product
upon
inflamm
bradykinin
rapidli
gener
induc
gene
express
activ
nfb
product
kininstimul
cell
may
also
exert
posit
effect
express
bradykinin
receptor
mediat
cellular
effect
kinin
thu
cross
talk
cytokin
kallikreinkinin
system
may
facilit
amplifi
inflammatori
respons
upon
influenza
viru
infect
identif
kallistatin
contribut
pathogenesi
influenza
viru
aid
understand
role
host
serin
proteas
inhibitor
viru
infect
result
provid
evid
first
time
kallistatin
impact
influenza
viru
infect
affect
cleavag
activ
ha
inflammatori
respons
find
suggest
inhibit
activ
kallistatin
inhibitor
may
explor
control
influenza
sinc
elisa
kit
quantifi
mous
kallistatin
level
commerci
avail
time
appropri
materi
quantifi
basal
induc
level
influenza
viru
infect
mice
result
obtain
mice
would
necessarili
resembl
patient
infect
influenza
viru
great
interest
analyz
level
kallistatin
bal
fluid
serum
patient
acut
influenza
studi
necessari
determin
whether
ratio
might
serv
earli
biomark
acut
influenza
viru
infect
sinc
proteolyt
activ
also
essenti
infecti
cycl
virus
besid
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
respiratori
parainfluenza
viru
whether
kallistatin
impact
infect
virus
warrant
investig
grate
trono
ecol
polytechniqu
federal
de
lausann
lausann
switzerland
gener
provid
plasmid
gener
lentivir
vector
also
thank
j
r
wang
depart
medic
laboratori
scienc
biotechnolog
nation
cheng
kung
univers
tainan
taiwan
p
l
kuo
institut
clinic
medicin
colleg
medicin
kaohsiung
medic
univers
kaohsiung
taiwan
gener
provid
influenza
viru
cell
line
respect
work
support
grant
nation
scienc
council
taiwan
nsc
nsc
